© BusinessWire
29.01.2025
AMRX
LISTED
NASDAQ
Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025
News Preview
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET.
The financial results and li...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2025
ICLR
LISTED
NASDAQ
ICON plc Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call
News Preview
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will release financial results for the fourth quarter and full year 2024 results after the market closes on Wednesday, February 19, 2025. The company will hold a conference call and webcast to discuss its financial results a...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
29.01.2025
AGFB
LISTED
EURONEXT
Transforming Healthcare Imaging in New Jersey: Englewood Health Selects AGFA HealthCare's Cloud Solution
News Preview
Englewood Health sought an innovative cloud Enterprise Imaging Platform that could streamline clinical and administrative operations, and relieve current and future system infrastructure needs. They found that solution along with an alliance with the ideal partner, AGFA HealthCare. ENGLEWOOD, NJ / ACCESS Newswire / January 29, 2025 / Englewood Heal...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© ACCESS Newswire
29.01.2025
CLBX
LISTED
AIMX
Angle PLC Announces Analysis of CTC-DNA and ctDNA using Illumina assay
News Preview
NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing platformFindings in lung cancer show that CTCs can provide additional biomarkers not found in ctDNA from single blood sampleANGLE invited to present data at EACR-Illumina webinar on 6 February 2025 GUILDFORD, SURREY / ACCESS Newswire / January 29, 2025 / ANGLE pl...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
28.01.2025
GETI B
LISTED
STO
Getinge Year End Report 2024: Strong order intake and increased sales contributed to sharp improvement in margins
News Preview
GOTHENBURG, Sweden, Jan. 28, 2025 /PRNewswire/ -- "In 2024, Getinge had record sales and we finished off the year with a strong quarter. Both order intake and net sales increased significantly, also organically, with positive performance in all regions", says Mattias Perjos, CEO of Getinge.
Growth was particularly strong in ventilators, where Ge...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2025
GETI B
LISTED
STO
Getinge Year End Report 2024: Strong order intake and increased sales contributed to sharp improvement in margins
News Preview
GOTHENBURG, Sweden, Jan. 28, 2025 /PRNewswire/ -- "In 2024, Getinge had record sales and we finished off the year with a strong quarter. Both order intake and net sales increased significantly, also organically, with positive performance in all regions", says Mattias Perjos, CEO of Getinge.
Growth was particularly strong in ventilators, where Ge...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2025
CU6
LISTED
ASX
Clarity to present COBRA and CLARIFY abstracts at two world-leading conferences
News Preview
Highlights
Two abstracts on Clarity's diagnostic COBRA and CLARIFY trials with 64Cu-SAR-bisPSMA have been accepted for presentation at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2025.An abstract on the COBRA study has also been selected for presentation at the American Urological Association (AUA) Annual M...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2025
ZLAB
LISTED
NASDAQ
Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its fourth quarter and full year 2024 financial results and provide recent corporate updates on February 27, 2025, before the opening of the U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT).
Confer...
Themefolio
Profiler
Peergroup
© Newsfile
28.01.2025
COPN
LISTED
SIX
Invitation to Cosmo's Unaudited Full Year 2024 Financial Results Webcast on 6 March 2025
News Preview
Dublin, Ireland--(Newsfile Corp. - January 28, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN: C43) (“Cosmo”) announced today that it will publish its unaudited Full-Year 2024 results on Thursday, 6 March 2025 at 7:00 am CET. Live conference call and video webcast presentation: Cosmo invites investors...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
28.01.2025
AGFB
LISTED
EURONEXT
AGFA HealthCare at HIMSS 2025: Revolutionizing Enterprise Imaging with Innovation and Work-Life Balance
News Preview
Empowering healthcare IT departments to experience Grow, Work, and Life - In Balance, with AGFA HealthCare's unified, purpose-built, modern Enterprise Imaging Platform. GREENVILLE, SOUTH CAROLINA / ACCESS Newswire / January 28, 2025 / As the demand for medical imaging surges, IT departments face growing pressures to keep up the pace and adopt the l...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2025
INTEG B
LISTED
STO
Integrum Partners with SPS to Expand 2025 Education Calendar, Enhancing Learning Opportunities
News Preview
MÖLNDAL, Sweden, Jan. 28, 2025 /PRNewswire/ -- Integrum, (STO: INTEG) , the leader in innovative bone-anchored prosthetic solutions, is proud to announce the expansion of their 2025 Education Calendar. In collaboration with Southern Prosthetic Supply (SPS), the leading U.S. distributor of orthotic and prosthetic (O&P) products, and other lead...
Themefolio
Profiler
Peergroup
© EQS Newswire
28.01.2025
DIM
LISTED
EURONEXT
Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2024
News Preview
Sartorius Stedim Biotech SA
/ Key word(s): Annual Results/Quarter Results
Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2024 28-Jan-2025 / 07:04 CET/CEST
Aubagne, France | January 28, 2025Sartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2024
Sales revenue at 2,780 ......
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
28.01.2025
SRT3
LISTED
XETR
Sartorius schließt Geschäftsjahr 2024 mit sehr gutem 4. Quartal und positivem Trend ab; Gesamtjahresprognose erreicht
News Preview
Göttingen, 28. Januar 2025
Sartorius schließt Geschäftsjahr 2024 mit sehr
gutem 4. Quartal und positivem Trend ab; Gesamtjahresprognose erreicht
Vorläufige Geschäftsergebnisse für 2024: Umsatz bei 3.381 Millionen Euro (+0,1 Prozent wechselkursbereinigt), operative Ertragsmarge erreicht 28,0 Prozent
Auftragseingang + 10,8 Prozent, zunehmende Na......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.01.2025
SRT3
LISTED
XETR
Sartorius closes fiscal 2024 with very good fourth quarter and positive trend; full-year guidance achieved
News Preview
Göttingen, Germany | January 28, 2025
Sartorius closes fiscal 2024 with very good fourth quarter and positive trend; full-year guidance achieved
Preliminary business results for 2024: sales revenue at 3,381 million euros (+ 0.1 percent in constant currencies), underlying profit margin reaches 28.0 percent
Order intake + 10.8 percent, demand i......
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2025
ORNBV
LISTED
HEL
Orion publishes Financial Statement Release for 2024 and holds a webcast on 25 February 2025
News Preview
ORION CORPORATION PRESS RELEASE 28 JANUARY 2025 at 09.00 EET...
Themefolio
Profiler
Peergroup
© EQS Newswire
27.01.2025
EUZ
LISTED
XETR
Deutlicher Anstieg bei Umsatz und bereinigtem EBIT
News Preview
Geschäftsjahr 2024 (vorläufig):
Umsatz: rund 295 Mio. EUR (VJ: 246,1 Mio. EUR)
EBIT vor Sondereinflüssen: rund 66 Mio. EUR (VJ: 46,9 Mio. EUR)
Nettogewinn: rund 33 Mio. EUR (VJ: 26,3 Mio. EUR)
Berlin, 27. Januar 2025. Die Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) hat nach vorläufigen, ungeprüften Zahlen für das GJ 2024 einen Konzernums......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.01.2025
EUZ
LISTED
XETR
Significant Increase in Sales and Adjusted EBIT
News Preview
Financial Year 2024 (preliminary):
Sales of around EUR 295 million (previous year: EUR 246.1 million)
EBIT before special items of around EUR 66 million (previous year: EUR 46.9 million)
Net Income of around EUR 33 million (previous year: EUR 26.3 million)
Berlin, 27 January 2025. According to preliminary, unaudited figures, Eckert & Ziegle......
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2025
ORY
LISTED
BME
ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders’ Meeting
News Preview
MADRID and CAMBRIDGE, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces significant changes to its Board of Directors at the upcoming Shareholders' Meeting, sched...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2025
BAVA
LISTED
CPH
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
News Preview
COPENHAGEN, Denmark, January 27, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 9, 2025, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 9, 2025 to February 5, 2025. The program is executed in accordance with Regulation...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2025
BIOA B
LISTED
STO
FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US
News Preview
STOCKHOLM, Jan. 27, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's Supplemental Biologics License Application (sBLA) for Leqembi as a once every four weeks intravenous (IV) maintenance dosing. Leqembi is indicated for the...
Themefolio
Profiler
Peergroup
© PR Newswire
27.01.2025
BIOA B
LISTED
STO
FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US
News Preview
STOCKHOLM, Jan. 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's Supplemental Biologics License Application (sBLA) for Leqembi as a once every four weeks intravenous (IV) maintenance dosing. Leqembi is indicated for the...
Themefolio
Profiler
Peergroup
© PR Newswire
24.01.2025
CU6
LISTED
ASX
Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer
News Preview
SYDNEY, Jan. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
24.01.2025
CLBX
LISTED
AIMX
Angle PLC Announces Parsortix Used in Research Paper from ETH Zurich
News Preview
CLINICAL TRIAL POWERED BY PARSORTIX SYSTEM PROVIDES FIRST-IN-CLASS data FOR NOVEL APPROACH TO CANCER treatmentParsortix system used to identify patients with highly metastatic CTC clusters for targeted treatmentNew treatment strategy provides 'uncharted opportunity' to target metastasis responsible for the vast majority of cancer deaths GUILDFORD,...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.01.2025
GMAB
LISTED
CPH
Grant of Restricted Stock Units and Warrants to Employees in Genmab
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© ActuNews
23.01.2025
ALTHX
LISTED
EURONEXT
THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2025
News Preview
Lyon, France – January 23, 2025, 6:00 PM CET - Theranexus, an innovative biopharmaceutical company in the treatment of rare neurological diseases, today announces its financial communication agenda for 2025. Each publication will be released after Euronext market closing, unless otherwise specified. These dates are given as an indication, the...
Themefolio
Profiler
Peergroup
© ActuNews
23.01.2025
ALTHX
LISTED
EURONEXT
THERANEXUS PUBLIE SON AGENDA FINANCIER POUR L'EXERCICE 2025
News Preview
THERANEXUS PUBLIE SON AGENDA FINANCIER POUR L'EXERCICE 2025
Lyon, France – 23 janvier 2025, 18h00 CET – Theranexus, société biopharmaceutique innovante dans le traitement des maladies neurologiques rares, publie aujourd'hui son agenda financier pour l'année 2025. Les publications auront lieu après...
Themefolio
Profiler
Peergroup
© BusinessWire
23.01.2025
AMRX
LISTED
NASDAQ
Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin
News Preview
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved memantine/donepezil 14-10 mg and 28-10 mg extended-release capsules, which references Abbvie’s NAMZARIC®, and Everolimus 2 mg, 3 mg and 5 mg extended-release capsules, which references Novartis’ AFIN...
Themefolio
Profiler
Peergroup
© PR Newswire
23.01.2025
TRAW
LISTED
NASDAQ
Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu
News Preview
Phase I completed in healthy volunteers with pharmacokinetic data supporting dosing for both therapeutic and further development for bird flu prevention
NEWTOWN, Pa., Jan. 23, 2025 /PRNewswire/ -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small molecule...
Themefolio
Profiler
Peergroup
© BusinessWire
23.01.2025
ZLAB
LISTED
NASDAQ
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ZL-1310, a potential highly active first-in-class DLL3 antibody-drug conjugate (ADC), for the treatment of small cell lung cancer (SCLC).
“Receiving an Orphan Drug Designation for ZL-1310 recognizes...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2025
SLP
LISTED
NASDAQ
Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2025
GMAB
LISTED
CPH
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2025
COLO B
LISTED
CPH
Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET (correction)
News Preview
Tuesday, 4 February 2025 at 11.00 - 12.00am CET (corrected from 10.00 - 11.00am CET in an earlier version of this invitation)In connection with the publication of Coloplast’s interim financial results for Q1 2024/25, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial results and answer questio...
Themefolio
Profiler
Peergroup
© EQS Newswire
22.01.2025
EVT
LISTED
XETR
Evotec erhält Fördermittel von der koreanischen Regierung zur Entwicklung neuartiger Antikörper-basierter Behandlungen für Lungenerkrankungen
News Preview
Yonsei University, Zymedi und Evotec erhalten 4,5 Mio. USD von dem Korea Institute of Advanced Technology im Rahmen des koreanischen Ministeriums für Handel, Industrie und Energie.
Die Finanzierung unterstützt eine neuartige Zusammenarbeit zur Entwicklung von First-in-Class-Therapeutika zur Behandlung von Asthma und idiopathischer Lunge......
Themefolio
Profiler
Peergroup
© EQS Newswire
22.01.2025
EVT
LISTED
XETR
Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases
News Preview
Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and Energy
Funding supports a novel collaboration to develop first-in-class therapeutic antibodies to treat asthma and idiopathic pulmonary fibrosis
Hamburg, Germany, 22 Janu......
Themefolio
Profiler
Peergroup
© ACCESS Newswire
22.01.2025
EVT
LISTED
XETR
Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases
News Preview
Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and EnergyFunding supports a novel collaboration to develop first-in-class therapeutic antibodies to treat asthma and idiopathic pulmonary fibrosis HAMBURG, GERMANY / ACCESS Newswire / January 22,...
Themefolio
Profiler
Peergroup
© BusinessWire
21.01.2025
LIVN
LISTED
NASDAQ
LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2024 results on Tuesday, February 25, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its fourth-quarter and full-year 2024 results prior to the call.
The audiocast will be a...
Themefolio
Profiler
Peergroup
© BusinessWire
21.01.2025
TEM
LISTED
NASDAQ
Tempus Announces National Launch of olivia, its AI-enabled Personal Health Concierge App for Patients
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of olivia. olivia is an AI-enabled personal health concierge app designed to empower patients by bringing their health-related data into one central location and leveraging advanced AI t...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.01.2025
COLO B
LISTED
CPH
Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET
News Preview
Tuesday, 4 February 2025 at 10.00 - 11.00am CETIn connection with the publication of Coloplast’s interim financial results for Q1 2024/25, to be released same day around 07.30am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on...
Themefolio
Profiler
Peergroup
© BusinessWire
21.01.2025
ERF
LISTED
EURONEXT
Eurofins Environment Testing Eaton Analytical Launches Groundbreaking Chloronitramide Anion Testing for Drinking Water
News Preview
Eurofins Environment Testing Eaton Analytical, part of the Eurofins Environment Testing network of laboratories in the US and a leader in water quality analysis, has introduced a cutting-edge method to detect chloronitramide anion, a newly identified disinfection byproduct (DBP), in drinking water. This innovation follows a pivotal study published...
Themefolio
Profiler
Peergroup
© PR Newswire
21.01.2025
SOBI
LISTED
STO
Invitation: Sobi's Q4 and FY 2024 report
News Preview
Sobi plans to publish its report for the fourth quarter and full year of 2024 on 5 February 2025 at 08:00 CET.
STOCKHOLM, Jan. 21, 2025 /PRNewswire/ -- Investors, analysts, and the media are invited to a conference call on the same day at 14:30 CET, 13:30 GMT, and 08:30 EST. The call will include a presentation of the results and a Q&A sessio...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.01.2025
IBAB
LISTED
EURONEXT
IBA and Wallonie Entreprendre International secure 30% stake in mi2-factory to support improved efficiency of silicon carbide-powered devices
News Preview
...
Themefolio
Profiler
Peergroup
© ActuNews
20.01.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgeving van Atlas Special Opportunities LLC
News Preview
Leuven, BELGIË – 20 januari 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgeving heeft ontvangen:
Oxurion ontving een transpara...
Themefolio
Profiler
Peergroup
© ActuNews
20.01.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
News Preview
Leuven, BELGIUM – January 20, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows:
Oxurion received a transparency notification on January 16, 2025, from...
Themefolio
Profiler
Peergroup
© PR Newswire
20.01.2025
IMMNOV
LISTED
STO
Immunovia AB announces outcome of exercise of warrants series TO 2
News Preview
LUND, Sweden, Jan. 20, 2025 /PRNewswire/ -- The exercise period for warrants series TO 2 (the "Warrant Programme") in Immunovia AB (publ) ("Immunovia" or the "Company") ended on 16 January 2025. A total of 92,197,387 warrants were exercised for the subscription of 92,197,387 new shares, corresponding to an exercise rate of approximately 74.1 perc...
Themefolio
Profiler
Peergroup
© PR Newswire
20.01.2025
IMMNOV
LISTED
STO
Immunovia AB announces outcome of exercise of warrants series TO 2
News Preview
LUND, Sweden, Jan. 20, 2025 /PRNewswire/ -- The exercise period for warrants series TO 2 (the "Warrant Programme") in Immunovia AB (publ) ("Immunovia" or the "Company") ended on 16 January 2025. A total of 92,197,387 warrants were exercised for the subscription of 92,197,387 new shares, corresponding to an exercise rate of approximately 74.1 perc...
Themefolio
Profiler
Peergroup
© BusinessWire
20.01.2025
BAYN
LISTED
XETR
Leaps by Bayer Announces One of the Largest Global Surveys of Society’s Attitudes Toward Breakthrough Technologies
News Preview
As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the launch of one of the largest surveys examining global public sentiment towards transformative technology. The field work was conducted by market research company Ipsos. The...
Themefolio
Profiler
Peergroup
© EQS Newswire
20.01.2025
FYB
LISTED
XETR
Formycon erhält EU-Zulassung für FYB203 (Aflibercept), ein Biosimilar zu Eylea®, unter den Markennamen AHZANTIVE® und Baiama®
News Preview
Pressemitteilung // 20. Januar 2025
Formycon erhält EU-Zulassung für FYB203 (Aflibercept), ein Biosimilar zu Eylea®, unter den Markennamen AHZANTIVE® und Baiama®
FYB203 (Aflibercept) zur Behandlung von neovaskulärer altersbedingter Makuladegeneration (nAMD) sowie mehreren weiteren schweren Netzhauterkrankungen zugelassen
AHZANTIVE® und Baiama® b......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.01.2025
FYB
LISTED
XETR
Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama®
News Preview
Press Release // January 20, 2025
Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama®
FYB203 (aflibercept) approved for the treatment of neovascular age-related macular degeneration (nAMD) and several other severe retinal diseases
AHZANTIVE® and Baiama® offer patients treat......
Themefolio
Profiler
Peergroup
© Globe Newswire
20.01.2025
BAVA
LISTED
CPH
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
News Preview
COPENHAGEN, Denmark, January 20, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 9, 2025, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 9, 2025 to February 5, 2025. The program is executed in accordance with Regulation...
Themefolio
Profiler
Peergroup
© BusinessWire
17.01.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults.
“There are more than 8 million patients living with schizophrenia in China who face significant unmet needs due to the limited...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.01.2025
AUTL
LISTED
NASDAQ
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings
News Preview
Autolus Therapeutics Presents Clinical Data Updates at the 2025 Tandem Meetings...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.01.2025
IBAB
LISTED
EURONEXT
IBA announces Chief Financial Officer transition
News Preview
Louvain-La-Neuve, Belgium, January 17, 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that Soumya Chandramouli will be stepping down from her role as Chief Financial Officer (“CFO”), effe...
Themefolio
Profiler
Peergroup
© ActuNews
16.01.2025
ALTHX
LISTED
EURONEXT
THERANEXUS : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital
News Preview
Lyon, France - 16 janvier 2025, 18h00 CET – Theranexus, société biopharmaceutique innovante dans le traitement des maladies neurologiques rares, publie le nombre d'actions composant son capital et le nombre total de droits de vote (articles L. 233-8 II du code de commerce et 223-16 du règlement général d...
Themefolio
Profiler
Peergroup
© PR Newswire
16.01.2025
VITR
LISTED
STO
Conference call full year report 2024: Vitrolife AB (publ)
News Preview
GOTHENBURG, Sweden, Jan. 16, 2025 /PRNewswire/ -- Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the fourth quarter and full year report 2024. The presentation will be held in English.
Time: Thursday 30 January, 2025 at 10.00 a.m. CET.To attend the conference call, please use this link to register. After regis...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.01.2025
POAI
LISTED
NASDAQ
Predictive Oncology Announces Planned European Launch of its ChemoFx® Treatment Selection Marker and Tumor Profiling Assay
News Preview
Initial plans target European clinical trials while providing standard testing to clinicians for individual patients...
Themefolio
Profiler
Peergroup
© BusinessWire
15.01.2025
HELP
LISTED
NASDAQ
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
News Preview
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the launch of its first strategic partnership agreement (“SPA”) with Segal Trial...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.01.2025
ORNBV
LISTED
HEL
Inside information: Orion upgrades full-year outlook for 2024 and provides preliminary information on financial performance for 2024
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION15 JANUARY 2025 at 18:25 EET...
Themefolio
Profiler
Peergroup
© BusinessWire
15.01.2025
TEM
LISTED
NASDAQ
Tempus Announces the National Launch of FDA-Approved xT CDx Test
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the company’s FDA-approved, NGS-based in vitro diagnostic device, xT CDx. Beginning today, xT CDx is now available for all ordering clinicians nationwide. xT CDx is a FDA-approved tes...
Themefolio
Profiler
Peergroup
© PR Newswire
15.01.2025
INTEG B
LISTED
STO
Integrum partners with Intelerad to Streamline Surgical Planning and Enhance Patient Outcomes in the US
News Preview
MÖLNDAL, Sweden, Jan. 15, 2025 /PRNewswire/ -- Integrum AB (publ), ticker (STO: INTEG), the medical technology company that provides the bone-anchored OPRA® Implant System to amputees, partners with Intelerad to Streamline Surgical Planning and Enhance Patient Outcomes
As part of its commitment to innovation and patient care, Integrum provides c...
Themefolio
Profiler
Peergroup
© BusinessWire
15.01.2025
ZLAB
LISTED
NASDAQ
Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the China subpopulation of the global Phase 3 innovaTV 301 study, demonstrating a clinically meaningful improvement in overall survival with TIVDAK treatment for patients with previously treated recurrent or metastatic cervical cancer compared to chemotherapy....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
